Future studies should focus on examining a greater number of tissue samples using immunohistochemistry to further validate the diagnostic value of ARPC1B and exploring the impact of ARPC1B on the tumor microenvironment, metabolism, drug resistance, and radiotherapy resistance in ovarian cancer. This evidence concerns the gene ARPC1B and ovarian cancer.